Why Juno Therapeutics Shares Vaulted 46% Higher in August

Why Juno Therapeutics Shares Vaulted 46% Higher in August

After Gilead Sciences (NASDAQ: GILD) scooped up competitor Kite Pharma (NASDAQ: KITE) for $11.9 billion and Novartis (NYSE: NVS) secured an approval from the Food and Drug Administration for Kymriah, shares of Juno Therapeutics (NASDAQ: JUNO) skyrocketed 46% in August, according to S&P Global Market Intelligence.

Juno Therapeutics hasn't been in the lead in the race to develop cellular therapies for cancer treatment for a while, but that didn't stop investors from flocking to its shares following key advances at its top CAR-T competitors.

IMAGE SOURCE: GETTY IMAGES.

Continue reading

Source: Fool.com